Advertisement

IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT

  • Yaping LuoEmail author
  • Qingqing Pan
  • Wen Zhang
Image of the Month
Part of the following topical collections:
  1. Image of the month

Notes

Funding information

This work was financially supported by the CAMS Initiative for Innovative Medicine (CAMS-I2M, 2017-I2M-3-001).

Compliance with ethical standards

The study was approved by the institutional review board of our hospital, and written informed consent for publication of this report was obtained from the patient.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol. 2010;17:303–32.Google Scholar
  2. 2.
    Smyrk TC. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol. 2011;23:74–9.CrossRefGoogle Scholar
  3. 3.
    Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of novel FAP-targeted radiotracers with improved tumor retention. J Nucl Med. 2019.  https://doi.org/10.2967/jnumed.118.224469
  5. 5.
    Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineChinese Academy of Medical Sciences and Peking Union Medical College HospitalBeijingPeople’s Republic of China
  2. 2.Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear MedicineBeijingPeople’s Republic of China
  3. 3.Department of RheumatologyChinese Academy of Medical Sciences and Peking Union Medical College HospitalBeijingPeople’s Republic of China

Personalised recommendations